Sarcomas are heterogeneous connective tissue tumors that occur at various anatomic sites and are generally difficult to treat. Cell states in sarcoma ecosystems are now shown to be conserved across multiple subtypes and associated with response to immunotherapy and patient outcome.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Burningham, Z., Hashibe, M., Spector, L. & Schiffman, J. D. Clin. Sarcoma Res. 2, 14 (2012).
van der Graaf, W. T. A., Tesselaar, M. E. T., McVeigh, T. P., Oyen, W. J. G. & Fröhling, S. Semin. Cancer Biol. 84, 228–241 (2022).
Suehnholz, S. P. et al. Cancer Discov. 14, 49–65 (2023).
Horak, P. et al. Cancer Discov. 11, 2780–2795 (2021).
Jerby-Arnon, L. et al. Nat. Med. 27, 289–300 (2021).
Wei, Y. et al. Nat. Cancer 3, 961–975 (2022).
DeMartino, J. et al. Nat. Commun. 14, 3074 (2023).
Danielli, S. G. et al. Sci. Adv. 9, eade9238 (2023).
Yuan, L. L. et al. Front. Immunol. 13, 1019870 (2022).
, A. et al. Nat. Cancer https://doi.org/10.1038/s43018-024-00743-y (2024).
Luca, B. A. et al. Cell 184, 5482–5496.e28 (2021).
Newman, A. M. et al. Nat. Biotechnol. 37, 773–782 (2019).
Petitprez, F. et al. Nature 577, 556–560 (2020).
Italiano, A. et al. Nat. Med. 28, 1199–1206 (2022).
Tawbi, H. A. et al. Lancet Oncol. 18, 1493–1501 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.F. reports consultancy fees from Bayer, Illumina and Roche; honoraria from Amgen, Eli Lilly, PharmaMar and Roche; research funding from AstraZeneca, Pfizer, PharmaMar and Roche; and travel or accommodation expense reimbursement from Amgen, Eli Lilly, Illumina, PharmaMar and Roche.
Rights and permissions
About this article
Cite this article
Wagner, J., Fröhling, S. Sarcoma ecotypes determine immunotherapy benefit. Nat Cancer 5, 536–538 (2024). https://doi.org/10.1038/s43018-024-00762-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-024-00762-9